BEA 2180 BR
Sponsors
Boehringer Ingelheim
Conditions
HealthyPulmonary Disease, Chronic Obstructive
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers
CompletedNCT02254122
Start: 2004-05-31Updated: 2014-10-01
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
CompletedNCT02263976
Start: 2003-08-31Updated: 2014-10-15
Phase 2
Dose Finding Study in COPD
CompletedNCT00122434
Start: 2005-07-31Updated: 2017-12-28
High Dose Trial in COPD
CompletedNCT00128440
Start: 2005-08-31Updated: 2013-10-29
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
CompletedNCT00528996
Start: 2007-09-06End: 2009-05-05Updated: 2021-08-24
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
CompletedNCT02242279
Start: 2004-06-30Updated: 2014-09-17